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Adenovirus (Ad) infection in humans is associated with inflammatory responses and thrombocytopenia.
Although several studies were conducted in mice models to understand molecular and cellular mecha-
nisms of Ad-induced inflammatory responses, only few of them turned their interest toward the mecha-
nisms of Ad-induced thrombocytopenia. Using different depletion methods, the present study ruled out
any significant role of spleen, macrophages, and vitamin K-dependent factor in Ad-induced thrombocy-
topenia. Interestingly, mice displaying thrombocytopenia expressed high levels of cytokines/chemokines
after Ad administration. Most importantly, pseudotyping adenovirus with the fiber protein from other
serotypes was associated with reduction of both cytokine/chemokine production and thrombocytopenia.
Altogether, our results suggest that capsid fiber protein (and more precisely its shaft) of Ad serotype 5
triggers the cytokine production that leads to Ad-induced thrombocytopenia.
INTRODUCTION
ADENOVIRUSES (AD) CORRESPOND TO a large family of
nonenveloped viruses. Among them, human Ad
from serotype 5 (Ad5), responsible for mild lung
disease, is the best characterized and has been en-
gineered to derive vectors that are attractive tools
for gene therapy. These vectors contain a core sur-
rounded by a capsid mainly composed by hexon, fi-
ber, and penton base proteins. Ad5 cell infection
in vitro occurs first via fiber protein knob binding
to the Coxsackie and Ad receptor also known as
CAR.1 Then, integrins acting as coreceptors interact
with the virus through an RGD motif of the penton
base protein to facilitate virus internalization.2
Direct vector administration into the blood-
stream is associated with several toxicities and
acute responses. For example, a strong hepatic tro-
pism leads to liver toxicity and damages.3,4 The liver
transduction was linked to the ability of Ad hexon
protein to interact with coagulation factor X (FX),
allowing subsequent virus binding to heparan sul-
fate proteoglycans expressed on hepatocytes.5–7 In-
terestingly, several studies have reported that
mutations of the main capsid components or their
replacement by proteins from other Ad serotypes
also result in reduced hepatocyte transduction.8–12
Besides liver toxicity, the triggering of an acute in-
flammatory response and cytokine production
within hours after virus administration represents
one of the major hurdles to Ad gene therapy.6
Once into the bloodstream, Ad can interact with
many circulating blood cells, including human
erythrocytes,13 peripheral bloodmononuclear cells,14
neutrophils,15 dendritic cells,16 and platelets.17 Par-
ticularly, an important decrease in platelet count
known as thrombocytopenia was associated with Ad
infection, both in preclinical studies18 and in clinical
trials.19–21 How Ad trigger thrombocytopenia is still
poorly understood. Some studies have demonstrated
thatAd canbinddirectly to platelets and trigger their
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activation and aggregation both in vitro and
in vivo.17,22 In contrast, another study reported
that Ad is not able to interfere with or potentiate
platelet aggregation.23 The involvement of Ad
primary receptor CAR and integrins in platelet
interaction is also controversial. Indeed, two
conflicting results were obtained regarding CAR
expression on human platelets.22,24 Finally, al-
though different integrin ligands were able to
block Ad binding to platelets in vitro,22 a recent
study questioned the role of integrins because
blocking aIIbb3 and avb3 integrins does not mod-
ify Ad binding and activation of platelets.25 Stu-
dies of Ad-induced thrombocytopenia in different
knockout (KO) mouse models helped to identify
the role of specific soluble host factors. For ex-
ample, Ad administration in Von Willebrand
factor (VWF) KO mice did not trigger a signifi-
cant thrombocytopenia compared with wild-type
(wt) mice, thereby suggesting a key role of VWF
in Ad-associated thrombocytopenia.26 Also, the
lack of thrombocytopenia in mice deficient for C3
and factor B proteins suggests a role for these
complement factors in this phenomenon.27 Fi-
nally, both genetic and acquired (pretreatment
with neutralizing antibodies) deficiencies in
TNF-a improved Ad-induced thrombocytopenia,
suggesting a role for TNF-a pathway in this
phenomenon.28
In the present study, we seek to go deeper in
the understanding of viral and host factors at
the origin of Ad-induced thrombocytopenia. Most
strikingly, we report a role of Ad5 fiber protein in
Ad-induced thrombocytopenia.
MATERIALS AND METHODS
Adenovirus
Adwt and AdF3 were previously described9 and
derived from Ad5 with E1 and E3 regions deleted.
AdS3K5 was obtained by replacing Ad5 shaft
(amino acid residues 47–400) by Ad3 shaft (amino
acid residues 46–132). All viruses contain an ex-
pression cassette with the promoter/enhancer from
the immediate early gene of human cytomegalovi-
rus (CMV), the Escherichia coli lacZ gene with
a nuclear localization signal, and the SV40 late
polyA signal. eGFP recombinant and E1-deleted
serotype 3 (Ad3) was described previously.29 Luci-
ferase recombinant Ad pseudotypedwith fiber from
serotype 35 (AdF35) was described previously.30
All viruses were obtained using standard proce-
dures as described,31 stored at -80C in PBS and
7% glycerol, and titrated by spectrophotometry
(1 OD260=1.1 ·1012 viral particles [vp]/ml).
In vivo experiments
All animal experimental procedures were con-
ducted in accordance with the institutional guide-
lines of Gustave Roussy Institutional Animal Care
and Use Committee. Six- to eight-week-old female
C57BL/6 (Harlan, France) mice were intrave-
nously (i.v.) injected into the retro-orbital plexus
with 5·1010, 1011, or 2· 1011 vp of corresponding
vectors. Blood from the retro-orbital plexus of mice
was collected in citrated tubes at the indicated time
points after virus administration. Platelets were
counted using an automated counter of blood cells
(MS9; Schloessing Melet).
For mice splenectomy, C57BL/6 mice were an-
esthetized and the lateral area of the animal left
side was shaved. A 3–4 cm incision was made and
the spleen was removed from the visceral cavity
and the blood vessels were cauterized. Five days
later, mice were i.v. injected with Ad and platelets
were counted 2 days later as described above.
Kupffer cell and coagulation factor depletion
Two approaches were used to induce Kupffer
cells (KC) depletion. The predosing method con-
sists of injection of 3· 1010 vp of AdGFP 4hr before
vector administration.32 KC depletion was alter-
natively induced with intravenous administration
of 200ll of clodronate-liposomes or PBS-liposomes
as negative control 24hr before Ad administration.
Transient KC elimination was confirmed by liver
section immunolabelling with F4/80 antibody. For
coagulation factor depletion, mice were injected
subcutaneously with 133lg of warfarin in 100ll of
PBS at 3 and 1 day before Ad delivery as previously
described.5
Cytokine and chemokine measurement
Spleens harvested 1hr after intravenous Ad
administration (1011 vp) were homogenized in sam-
ple buffer according to manufacturer’s instructions.
Lysates were incubated overnight with membranes
from Proteome Profiler Antibody array (Mouse Cy-
tokine Array Panel A; R&D System) according to
manufacturer’s instructions. Membranes were de-
veloped with HRP substrate and revealed using
ChemiDoc MP System (BioRad).
Interleukin-6 measurement
Blood samples were collected 6hr after Ad ad-
ministration and serum interleukin-6 (IL-6) was
quantified using a Duo-Set ELISA assay according
to manufacturer’s instructions (R&D).
FX measurement
Endogenous murine FX activity was determined
by an amidolytic assay using the Russel’s Viper
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Venom-X enzyme (RVV-X). In this assay, FX acti-
vation into FXa by the RVV-X leads to the cleavage
of the chromogenic substrate S-2765. Briefly,
plasma samples or a pool of plasma from wt C57Bl/
6 mice (used as standard) were diluted in TBS/BSA
(0.1%)/CaCl2 (5mM) and incubated with 0.5lM
RVV-X enzyme (Kordia Life Science) 5min at 37C.
The chromogenic substrate S-2765 (Chromogenix)
was added at 0.2mM and the kinetic reading
at 405nm was immediately started with a read-
ing every 30 sec over 20min. The Vmax (maximum
speed of chromogenic conversion) was calculated
for the linear part of the kinetic curve and plasma
sample valueswere normalized to the standard. FX
activity was expressed in units/ml.
Statistical analysis
Results were expressed as means – SEM. ANO-
VA analysis followed by Tukey’s post-hoc test was
used to compare sets of data. Variations were con-
sidered statistically significant when p< 0.05. All
graphs and statistical tests were performed using
GraphPad Prism software.
RESULTS AND DISCUSSION
Kinetics and dose dependency of Ad-induced
thrombocytopenia
First, we sought to determine the kinetics of
thrombocytopenia induction in response to Ad ad-
ministration. C57BL/6 mice were i.v. injected with
saline or two different doses of Ad (1011 and 2 ·1011
vp), and platelet counts were determined every day
during the first week and at day 15 postinfection
(p.i.) (Fig. 1). Ad injection caused a rapid decrease
in platelet count within 24hr p.i. with a nadir at
48hr p.i.. Of note, the reduction in platelet count
was more severe with the higher viral dose, dem-
onstrating the dose dependency of this phenome-
non (Fig. 1). However, the thrombocytopenia was
transient and mice recovered a normal platelet
count by day 5 p.i.. The kinetic of thrombocytopenia
induction and the dose dependency observed in our
study are in accordance with previous results ob-
tained by others in mice33 but also in rabbits,33
baboons,34 and rhesus monkeys.18
Blood coagulation factors and spleen are not
involved in Ad-induced thrombocytopenia
Coagulation factors and platelet activation are
complementary and mutually dependent processes
participating in hemostasis.35 Because Ad is able
to interact with different blood factors such as co-
agulation factor IX and X (FX),5 we evaluated
whether these factors play a role in Ad-induced
thrombocytopenia. To answer this question,C57BL/6
mice were pretreated with warfarin or saline at
days 3 and 1 before Ad administration, as described
previously.5 Blood factor depletion was confirmed
by the measurement of FX activity in mice sera
harvested before virus delivery (12.8– 3.2 in
warfarin-treated mice vs. 187.9– 54.7 in PBS-
treated mice). After Ad administration of 2 ·1011
(Fig. 2a) or 1011 vp (Fig. 2b), no statistically
significant difference in platelet counts was ob-
served between saline- or warfarin-pretreated
mice. These results ruled out any significant role of
coagulation factors in Ad-induced thrombocytope-
nia and are in accordance with the fact that hexon-
modified Ad that are disabled in FX interaction
triggered thrombocytopenia as efficiently as their
wt counterparts.8 Then, we analyzed the spleen
involvement in Ad-induced thrombocytopenia. In-
deed, the spleen is well-known as a site of platelet
storage able to release them upon request.36 In
addition, this organ removes old platelets from the
bloodstream.37 To assess the role of the spleen in
Ad-induced thrombocytopenia, C57BL/6 mice were
splenectomized or sham-treated 5 days before Ad
systemic administration, and platelet counts were
determined 48hr p.i. Both splenectomized and
nonsplectomized mice displayed a similar reduc-
tion in platelet numbers in response to Ad admin-
istration (Fig. 2c). In parallel, because the spleen
can store excessive numbers of platelets leading to
splenomegaly,37 we carefully examined the size of
the spleens of nonsplectomized mice and did not
observe signs of splenomegaly at day 2 after Ad
Figure 1. Kinetics of Ad-induced thrombocytopenia. Mice were injected
intravenously with PBS or with different doses (1011 and 2· 1011 vp) of Adwt.
Platelet counts were determined at different time points thereafter. n= 5
mice; means + SEM. Ad, adenovirus; Adwt, Ad bearing a wild-type capsid.
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administration (data not shown). Taken together,
these results demonstrated no significant role of
the spleen in Ad-induced thrombocytopenia. In
contrast, Hofherr et al. reported that splenectomy
protected mice from Ad-induced thrombocytope-
nia.3 The discrepancy between our results and
Hofherr et al. could be because of differences in
mice strains (C57BL/6 in our study and outbreed
ICR mice in the study of Hofherr et al.) and viral
doses used.
Requirement of the fiber shaft in Ad5-induced
thrombocytopenia
To address the question of viral proteins in-
volved in Ad-induced thrombocytopenia, we fo-
cused on capsid proteins known to participate in Ad
infection process. These proteins correspond to
hexon, penton base, and fiber proteins able to bind
to coagulation FX, integrins, CAR and heparan
sulfates, respectively. First, we ruled out a role for
hexon–FX interaction in Ad-induced thrombocy-
topenia because we reported previously that im-
pairing hexon binding to FX has no impact on
platelet counts.8 Second, previous data from our
laboratory based on the use of Ad disabled in in-
tegrin interaction ruled out any role for the penton
base protein in Ad-induced thrombocytopenia
(data not shown). Then, taking advantage of the
two already described serotype 5 recombinant Ad
pseudotyped with the fiber from serotype 3 (Vigne
et al.9 and Raddi et al., unpublished manuscript),
we investigated the role of the fiber protein.
C57BL/6 mice were injected i.v. with a high
(Fig. 3a), intermediate (Fig. 3b), or low (Supple-
mentary Fig. S1; Supplementary Data are available
online at www.liebertpub.com/hum) dose of Adwt,
AdF3, or AdS3K5. Both latter viruses express the
whole (shaft and knob) or only the shaft of Ad3 fiber,
respectively.WhereasAdwt triggered a strong drop in
platelet counts, fiber-modified Ads triggered a signif-
icantly reduced thrombocytopenia even at the highest
viral dose (Fig. 3a). Interestingly, although Adwt still
induced platelet reduction at the lowest dose of
5·1010 vp, fiber-modified Ad did not (Supplementary
Fig. S1).
These results suggest that either Ad5 fiber was
responsible for the induction of the thrombocyto-
penia or Ad3 fiber has an intrinsic property to
mitigate thrombocytopenia. To decipher between
these two hypotheses, C57BL/6 mice were injected
with 1011 vp of Adwt or a recombinant Ad3.
Figure 3c shows that Ad3 induces thrombocytope-
nia to the same extent as Adwt does, thus ruling
out a modulatory role of Ad3 fiber. On the other
hand, pseudotyping Ad5 with a fiber from sero-
type 35 (AdF35) strongly reduced virus-induced
thrombocytopenia (Fig. 3d). Altogether, these
results suggest that Ad5 fiber was involved in
Ad-induced thrombocytopenia. More precisely, be-
cause AdS3K5 also displayed a reduced thrombo-
cytopenia, this indicates a role for the Ad5 shaft in
this phenomenon. The fact that thrombocytopenia
was observed in clinical trials after administration
of an Ad pseudotyped with a chimeric fiber con-
taining Ad5 shaft and Ad3 knob further supports
our conclusions.38 However, it should be under-
lined that Ad displaying a targeting peptide within
the HI loop also led to a reduced thrombocytope-
nia.39 The discrepancy between our results (role
of the shaft) and their results (role of the knob)
may be linked to the different strains of mice
(C57BL/6 and BALB/c, respectively) used or alter-
natively to the targeting ligand used in Coughlan
et al.39
Figure 2. Coagulation factor and spleen involvement in Ad-induced thrombocytopenia. Mice were mock-treated (noninfected, NI) or treated with warfarin
before injection of 2· 1011 (a) or 1011 vp (b) of Adwt, and platelet counts were determined 2 days later. (c) C57B/6 mice were splenectomized or sham-
splenectomized 5 days before injection of Adwt (1011 vp) and platelet numbers were counted 2 days later. n= 2–5 mice; means + SEM. **p < 0.01 and
***p < 0.001 versus NI matched, treated control. ns, nonsignificant.
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Role of macrophages in Ad5-induced
thrombocytopenia
Different pathogens are able to interact with
platelets, leading to their uptake by liver KC.40
Whether or not Ad interact with platelets17,22,23
and whether KC play any role in platelet clearance
during virus infection17,41 are still a matter of de-
bate. Therefore, we investigated the potential role
of KC in the development of Ad-induced thrombo-
cytopenia using two depletion methods: predos-
Figure 3. Thrombocytopenia induction by fiber-modified Ad5 and Ad3. Mice were intravenously injected with 2· 1011 (a) or 1011 (b–d) vp of serotype 5 Ad
bearing a wild-type capsid (Adwt) or pseudotyped with AdF3 (a, b) or AdF35 fiber (d), or of serotype 3 Ad3 (c). Platelet counts were determined 2 days later. A
representative experiment out of three repeats is shown. n = 4–7 mice; means+ SEM. **p < 0.01 and ***p< 0.001 versus Adwt (a, b, d) or control group (c).
Figure 4. Role of Kupffer cells (KC) in Ad-induced thrombocytopenia. Mice were pretreated with or without Ad (predosing, a, b) or pretreated with PBS- or
clodronate-liposomes (c, d). After 4 or 24 hr, respectively, mice were injected with PBS or with 1011 vp of Adwt, AdF3, or AdS3K5. Platelet counts were
determined 2 days later and expressed relative to noninfected (NI) mice. One of two repeat experiments is shown; means and data for individual mice are
shown. *p < 0.05, **p< 0.01, and ***p < 0.001 versus NI group; ns, nonsignificant.
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ing,32 which consists of preadministration of a low
dose of Ad (3 · 1010 vp) able to specifically eliminate
KC, the resident liver macrophages, or pretreat-
ment with clodronate-liposomes that depletes any
macrophages.42 Regardless of the depletion meth-
od, comparison of platelet counts in control (Fig. 4a
and c) and in macrophage-depleted mice (Fig. 4b
and d) did not show any significant modification of
Adwt-induced thrombocytopenia. However, both
methods of depletion were able to abrogate the
modest reduction in platelet counts observed after
intravenous AdF3 or AdS3K5 delivery. Thus, al-
though macrophages do not appear to play a sig-
nificant role in Adwt-induced thrombocytopenia,
they may play a role in the modest thrombocyto-
penia triggered by Ad pseudotyped with Ad3 fiber.
Reduced inflammatory responses triggered
by Ad5 pseudotyped with the fiber
from other serotypes
Different studies have proposed that cytokine
production participates to Ad-induced throm-
bocytopenia.28,43,44 Therefore, we analyzed whe-
ther pseutotyping Ad5 with the fiber of serotype 3
Figure 5. Cytokine and chemokine production in response to Ad injection. Mice were intravenously injected with 1011 vp. (a) Spleen cytokine and chemokine
differentially induced 1 hr postinfection in Adwt-injected mice compared with PBS-injected mice are shown for Adwt, AdF3, and AdS3K5. For each Ad, data of
two mice are displayed. (b–d) Serum IL-6 production was determined by ELISA 6 hr after injection of Adwt, AdF3, AdS3K5 (1011 and 2· 1011 vp, b), Ad3 (1011 vp,
c), or AdF35 (1011 vp, d). One representative of two experiments is shown. n = 4–7, means + SEM. ***p < 0.001 versus noninfected (NI) group; n.s.,
nonsignificant.
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modifies cytokine and chemokine production in
response to intravenous Ad delivery. First, using
antibody arrays, we measured cytokine and che-
mokine production in the spleen harvested 1hr p.i.
(Fig. 5a). Compared with PBS-injected mice, Adwt-
injected mice displayed a strong production of cy-
tokines (IL-1b and IL-6), chemokines (IP-10, KC,
CCL2, CCL3, and CXCL2), as well as complement
factor C5a and triggered receptor expressed on
myeloid cells-1 (TREM-1). Interestingly, AdF3 and
AdS3K5 induced a weak production of these cyto-
kines and chemokines in the spleen, comparable to
the one observed in the spleen from PBS-injected
mice (Fig. 5a). Using ELISA, we observed a strong
dose-dependent release of IL-6 in the blood 6hr
after Adwt administration. However, both AdF3-
and AdS3K5-injected mice displayed a dramatic
reduction in IL-6 production (Fig. 5b), at both viral
doses. To exclude a putative inhibitory effect of Ad3
fiber (and more precisely Ad3 shaft) on inflamma-
tory responses, C57BL/6 mice were injected with
Adwt or Ad3. As shown in Fig. 5c, compared with
Adwt, Ad3 led to a 20-fold higher production of
serum IL-6 (Fig. 5c), ruling out a role for Ad3 fiber
in decreasing cytokine and chemokine production.
The fact that AdF3 and AdS3K5, on the one hand,
and Ad3, on the other hand, present opposite cap-
abilities to trigger cytokine production and throm-
bocytopenia is puzzling. One hypothesis would be
that Ad3 shaft alone does not possess the intrinsic
property to trigger cytokine production and throm-
bocytopenia but needs other Ad3 capsomers. An
alternative hypothesis would be that insertion of
fiber from serotype 3 in Ad5 backbone led to a
particle trafficking different from Ad5, thus im-
pairing cytokine production. Interestingly, intra-
venous administration of AdF35 led to serum IL-6
levels comparable to noninfected mice (Fig. 5d).
Taken as a whole, our results argue for a role of
Ad5 shaft in cytokine and chemokine production.
These results are further supported by a previous
work showing that pseudotyping Ad5 with fiber
from serotypes 11 or 35 reduced IL-6 and TNF-a
production.45
Ad-induced thrombocytopenia is associated
with cytokine production
As stated above, Ad was reported by different
teams46 to trigger inflammatory cytokines pro-
duction as well as thrombocytopenia. Our present
results uncover that pseudotyping Ad5 with fibers
from other serotypes (Ad3 or Ad35) both reduces
cytokine production (Fig. 5) and ameliorates the
thrombocytopenia (Fig. 3). This suggests an un-
anticipated link between cytokine production
and thrombocytopenia. Interestingly, a point-by-
point comparison of IL-6 production and platelet
counts in individual mice demonstrated that Adwt-
injected mice displayed both high levels of serum
IL-6 and a reduction in platelet counts, whereas
mice injected with pseudotyped Ad exhibit reduced
level of IL-6 and high platelet counts (Fig. 6a and
b). However, our previous results showed that
thrombocytopenia occurred even in Ad-injected IL-
6-deficient mice.47 Taken together, these results
point out that IL-6 itself is not mandatory to this
phenomenon and suggests a role for other cyto-
kines.
To summarize, taking advantage of various
vectors (serotypes or pseudotyped Ad), we dem-
onstrated a role for Ad5-fiber protein and more
precisely for its shaft in Ad5-induced thrombocy-
topenia. We also reported that coagulation factors,
spleen, and macrophages were dispensable in this
phenomenon. In parallel, our results suggest that
Ad5 fiber—more precisely Ad5 shaft—plays a key
Figure 6. Relationship between IL-6 levels in mice sera and platelet counts. (a) Mice were injected with 1011 or 2 · 1011 vp of Adwt, AdS3K5, and AdF3. (b)
Mice were injected with 1011 vp of Adwt or AdF35. Serum IL-6 levels and blood platelet counts were measured 6 and 48 hr postinfection, respectively. Each dot
represents results from an individual mouse.
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role in induction of chemokines and cytokines. In-
terestingly, we draw a parallel between cytokine/
chemokine production and thrombocytopenia. In-
deed, using different Ads, our results show that
Ads able to trigger high levels of cytokines do elicit
strong thrombocytopenia. Mice injected with AdF3
and AdS3K5 displayed a reduction in C5a produc-
tion (Fig. 5a), suggesting a reduced activation of
the complement cascade. Since the complement
activation was proposed by others to be involved in
thrombocytopenia,48 the low C5a production in the
spleen of AdF3- and AdS3K5-injected mice could
explain their inability to induce thrombocytope-
nia. Further experiments are needed to better un-
derstand the link between cytokine production,
complement factors, and thrombocytopenia. By
showing the key role of theAd5 fiber protein in both
cytokine production and thrombocytopenia, this
study paves the way to a better understanding of
molecular and cellularmechanisms involved in Ad-
induced thrombocytopenia. Previous results of our
laboratory have shown that fiber-pseudotyped Ad
led to a reduced liver transduction upon intrave-
nous delivery but to efficient tumor gene transfer
upon direct intratumoral administration (Raddi
et al. unpublished manuscript). Altogether, the
results underline that fiber-pseudotyped Ad that
elicit low cytokine/chemokine production and re-
duced thrombocytopenia constitute tools of valu-
able interest for safer gene delivery in tumors.
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